Spero Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $11,802 | $5,874 | $9,356 | $13,469 |
Gross Profit | 11,802 | 5,874 | 9,356 | 13,469 |
EBITDA | -2,361 | -14,731 | -20,848 | -18,593 |
EBIT | -20,754 | -18,595 | ||
Net Income | -1,700 | -14,731 | -20,888 | -17,147 |
Net Change In Cash | 11,802 | 5,874 | 9,356 | 13,469 |
Free Cash Flow | -17,693 | -4,002 | -23,401 | 12,763 |
Cash | 31,194 | 48,887 | 52,889 | 76,290 |
Basic Shares | 56,026 | 55,376 | 54,037 | 54,124 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $27,396 | $96,735 | $48,579 | $18,256 |
Gross Profit | 27,394 | 96,368 | 5,916 | 17,139 |
EBITDA | -72,482 | 25,771 | -42,263 | -87,170 |
EBIT | -72,484 | 25,404 | -43,810 | -87,816 |
Net Income | -68,566 | 22,806 | -46,415 | -89,756 |
Net Change In Cash | 27,396 | 96,735 | 48,579 | 18,256 |
Free Cash Flow | -23,444 | -32,995 | -7,731 | -64,308 |
Cash | 52,889 | 76,333 | 109,107 | 112,584 |
Basic Shares | 54,037 | 52,989 | 37,585 | 30,895 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.03 |
2025-03-31 | -$0.24 |
2024-12-31 | -$0.36 |
